COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.

Ann Hematol · 2020 · PMC7312112 · PMID 32583086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Preliminary data confirmed the treatment safety (BJCP phase I) and showed a trend to a reduced 28-day mortality as compared with 28% in the placebo group ( www.adrenomed.com ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.